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Stress single-photon emission computed tomography (SPECT)
myocardial perfusion imaging is a historically robust, nonin-
vasive technique, and represents the most common imaging
method used in the United States for evaluation of patients
with suspected or known coronary artery disease (CAD). On
the basis of its diagnostic and prognostic evidence based
coupled with its familiarity of usedSPECT is endorsed for an
array of clinical indications within clinical practice guidelines.
In recent years, positron-emission tomography (PET) and
coronary computed tomography angiography (CTA) have
emerged as practical alternatives to SPECT, with con-
temporary published studies establishing a high diagnosticSee page 1002performance and prognostic utility that appears to match, if
not exceed, that of conventional SPECT imaging. Yet, for the
practitioner evaluating a patient being considered for nonin-
vasive imaging for CAD, the choice of these and other
noninvasive tests is ideally made, not only based upon
consideration of test performance, but also for the ability
of any test to inform therapeutic decision making in a timely,
deﬁnitive, clinically effective, and cost-efﬁcient manner.
Given the recent introduction and adoption of PET and
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are generally lacking, and thus, the role of PET or CTA in
daily clinical practice has yet to be precisely elucidated.
These issues were, in part, addressed by the SPARC
(Study of Myocardial Perfusion and Coronary Anatomy
Imaging Roles in Coronary Artery Disease) study, a pro-
spective observational registry designed to compare post-test
resource utilization and outcomes among patients who un-
derwent SPECT, PET, or 64-slice coronary CTA between
May 2006 and April 2008 (1). The SPARC investigators
previously reported that among 1,703 patients without
known CAD, patients referred for CTA experienced signif-
icantly higher 90-day rates of downstream invasive coronary
angiography (ICA) testing and new prescriptions for aspirin
and statins, as compared with those who underwent SPECT
or PET (2). However, the clinical outcome and costs among
these 3 testing cohorts have not been previously reported.
In this issue of the Journal, Hlatky et al. (3) extend their
prior work by reporting the 2-year estimated costs and
clinical outcomes among SPARC study participants without
prior known CAD. Further, the authors estimate the long-
term cost effectiveness of SPECT, PET, and CTA in
models based upon the observed intermediate-term rates
of all-cause mortality and myocardial infarction during
the study period. Recognizing the signiﬁcant differences in
study populations being referred to SPECT, PET and CTA,
the authors identiﬁed similar groups of individuals referred
to eachmodalitymatched by propensity scoring. Similar to the
initially reported 90-day results, the authors again observed
that patients who underwent coronary CTA and PET expe-
rienced higher rates of subsequent ICA (16% and 15%,
respectively) as compared with patients who underwent
SPECT (7%). Patients who underwent PET and CTA were
alsomore likely to undergo coronary revascularization,with the
majority of ICAand revascularization occurringwithin 90days
of index testing.Given an expected non-normal distribution of
costs associated with testing pathways, the median costs were
no different among patients undergoing SPECT and CTA.
Yet, despite the non-normality, mean costs were nevertheless
reported and were higher for CTA (15%) and PET (22%) as
compared with SPECT, stemming from higher rates of ICA
and revascularization. Whether these ﬁndings underscore a
superior diagnostic performance of CTA and PET compared
with SPECTdwith a higher rate of “true positive” patients
referred for ICAdor higher rates of therapeutic revasculari-
zation for symptomatic angina from obstructive CAD remains
unelucidated. Thus, although these data presented by the
SPARC investigators represent an important step forward to
address metrics beyond traditional measures of diagnostic and
prognostic test performance, they nevertheless highlight the
complexities associated with the conduct of such a study.
Given the observational design, patients enrolled into
SPARC were clinically referred to speciﬁc tests based upon
physician preference, a multifaceted decision that invariably
resided in the context, not only of test type, but also of
the results of prior testing, physician characteristics
Villines and Min JACC Vol. 63, No. 10, 2014
A SPARC.But Further Illumination Is Needed March 18, 2014:1009–10
1010(e.g., familiarity with test modality, board certiﬁcation),
patient variables (e.g., symptom type, pre-test probability of
CAD, patient preference), and test availability. Although
many of these “confounding” variables could not be
adequately accounted for within the SPARC registry, it is
perhaps notable that many sites within the study did not
even offer SPECT, PET, and CTA, thus rendering direct
comparison of the 3 tests impracticable. Within sites offer-
ing more than 1 of these modalities, the locations of the
imaging laboratories likely exhibited heterogeneity (ofﬁce-
versus hospital-based), and may have also contributed to
referral patterns during the study period. Further, although
standard clinical variables such as ejection fraction or renal
function were not routinely collected for the study, impor-
tant factors such as these likely inﬂuenced the choice of
“which test for which patient.” As an example, in addition to
signiﬁcant differences in age, comorbidities, and symptom
status between testing groups, only 4% of patients who
underwent SPECT had undergone any form of prior
ischemic testing as compared with 29% of patients under-
going CTA. This 7-fold difference suggests the use of CTA
as a “gatekeeper” or “arbiter,” in part for individuals with
stress tests that were abnormal or equivocal, respectively.
Notably, at its inception in 2006, the SPARC study hy-
potheses were and remain to this day novel and important.
A comparative study of noninvasive imaging tests for costs
and clinical outcomes that include 64-detector CTAda
modality introduced only in 2005dis as admirable as it had
been contemporary. Yet, in the past 7 years, the rapid tech-
nological evolution of SPECT, PET, and CTA has empha-
sized the concept of technology assessment as a “moving
target.” As one example, iterative gains in CTA technology
now enable test performance at radiation doses comparable to
screening mammography and 10-fold lower than current
generation single-isotope SPECT imaging (4). Similarly,
advances in dual-energy CT now enable iodinated contrast
doses up to 5-fold lower than traditional single-energy CTA.
Perhaps most prominently, the practice of CTA over the past
several years has gained, not only in utilization, but also in
familiarity, and changing practice patterns based upon CTA
test ﬁndings are now observed. Thus, although large-scale
prospective studies of noninvasive CAD imaging are vital to
our understanding of their integration into clinical practice, it
remains a vexing proposition to conduct long-term or even
intermediate-term investigationsdsuch as is the case for
SPARCdthat represent a static moment in time for tech-
nologies whose development effectively outpaces the study.
Finally, the results of the present study emphasize the
inextricable link between clinical effectiveness and economic
efﬁciency. Germane to this, rates of post-test death or
nonfatal myocardial infarction were highest for PET (6.5%),
followed by SPECT (2.8%) and then CTA (1.6%), with
patients undergoing PET older and with a greater prevalence
of co-morbidities. A risk-adjusted trend (p ¼ 0.07) was
observed for lower all-cause mortality in individuals under-
going CTA versus SPECT, and although a signiﬁcant beneﬁtfor CTA-based testing would be expected for a composite
of mortality and myocardial infarction, this was not reported.
Focused on SPECT as the conventional imaging test, the
cost effectiveness of CTA was $10,700 per life-year added,
with standard measures considering cost effectiveness at a
threshold <$50,000 per quality-adjusted life-years saved.
In the current study, CTA was cost effective in 89% of
the bootstrap analyses, even when assuming a conservative
estimate of 2 years of life lost due to myocardial infarction.
Although these data are interesting and informativedand
perhaps suggest a potential beneﬁt of CTA usedthe inﬂu-
ence of residual confounding related to the aforementioned
referral bias cannot be underestimated, particularly with
respect to the increased rates of death in patients undergoing
PET imaging. Further, post-test treatments and changes in
patient behavior may have resulted in signiﬁcant beneﬁts, as
well as harms associated with test-based strategies, and were
regrettably not collected in the study.
Despite all of these limitations, the authors of the present
study should be commended, not only for asking the right
questions comparing the more contemporary imaging tests
to more traditional ones, but also for guiding the ﬁeld of
noninvasive CAD imaging into investigations beyond diag-
nostic performance and prognostic utility.These observational
studies will serve as the predecessors to ongoing randomized
trials that will further inform the clinical practice community
as to the advantages and disadvantages of the use of “which test
when,” all the while acknowledging that the imaging ﬁeld is a
perpetually evolutionary process that must consider technol-
ogy development, test familiarity, and downstream testing and
treatment. In this regard, the present study represents a
“SPARC,” but further illumination is invariably needed.
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